Following its first FDA approval, for Inveltys (loteprednol etabonate ophthalmic suspension 1 percent) to treat inflammation and pain following ocular surgery, developer Kala Pharmaceuticals Inc. said it plans to hire a specialty sales force of about 60 reps to target 80 percent of likely prescribers in preparation to launch the ophthalmic suspension product early next year.